Bulletin N 149 - September 2025
Immunophenotypic characterisation of Chronic Lymphoproliferative Disorders in our healthcare catchment Area: EuroFlow screening results from Catlab
Lymphoproliferative syndromes (CLPS) are neoplasms of mature B, T, or NK lymphocytes with clonal expansion and progressive accumulation in the blood, bone marrow, and lymph nodes. The WHO 2022 classification divides them into CLPS-B and CLPS-T/NK. Multiparametric flow cytometry is a key tool in the differential diagnosis between reactive lymphocytosis and CLPS through the analysis of the lymphocyte immunophenotype with fluorochrome-labeled antibodies. The Euroflow consortium designed the diagnostic algorithm that includes the Lymphoid Screening Tube (LST), a panel with 12 antibodies that allows the detection of phenotypic alterations in the different lymphocyte lines and their classification. Twenty-seven percent corresponded to CLL-B, 2% to CLL-T/NK, 3% were not assessable, and 6% were follow-up cases. Among SLPC-B, chronic lymphocytic leukemia (CLL-B) was the most common, followed by marginal zone lymphoma. As for SLPC-T/NK, the most frequently detected was large granular T-cell leukemia. The most prevalent entity is CLL-B, often detected in asymptomatic patients thanks to screening in routine blood counts. Overall, approximately one-third of the SLPCs performed showed aberrant phenotypes, reproducing the higher prevalence of SLPC-B over T/NK already described in the literature. Catlab expertise proves Euroflow LST as a fast and reliable tool for SPLC screening, facilitating referral to hematology and improving early detection in the population within our healthcare catchment area.